PL2737081T3 - Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka - Google Patents

Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka

Info

Publication number
PL2737081T3
PL2737081T3 PL12740974T PL12740974T PL2737081T3 PL 2737081 T3 PL2737081 T3 PL 2737081T3 PL 12740974 T PL12740974 T PL 12740974T PL 12740974 T PL12740974 T PL 12740974T PL 2737081 T3 PL2737081 T3 PL 2737081T3
Authority
PL
Poland
Prior art keywords
chemotherapy
predicting
risk
response
breast cancer
Prior art date
Application number
PL12740974T
Other languages
English (en)
Inventor
Mathias Gehrmann
Karsten Weber
Ralf Kronenwett
Christoph Petry
Jan Brase
Original Assignee
Sividon Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics Gmbh filed Critical Sividon Diagnostics Gmbh
Publication of PL2737081T3 publication Critical patent/PL2737081T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL12740974T 2011-07-28 2012-07-30 Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka PL2737081T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11175852 2011-07-28
EP12740974.6A EP2737081B1 (en) 2011-07-28 2012-07-30 Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer

Publications (1)

Publication Number Publication Date
PL2737081T3 true PL2737081T3 (pl) 2017-04-28

Family

ID=46598521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12740974T PL2737081T3 (pl) 2011-07-28 2012-07-30 Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka

Country Status (7)

Country Link
US (4) US20140228241A1 (pl)
EP (2) EP2737081B1 (pl)
ES (2) ES2608322T3 (pl)
HU (1) HUE032391T2 (pl)
PL (1) PL2737081T3 (pl)
PT (1) PT2737081T (pl)
WO (1) WO2013014296A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030164T2 (en) 2010-03-31 2017-05-29 Sividon Diagnostics Gmbh A method of predicting breast cancer recurrence during endocrine treatment
DK2951317T3 (en) 2013-02-01 2018-01-15 Sividon Diagnostics Gmbh PROCEDURE FOR PREDICTING THE BENEFIT OF INCLUSING TAXAN IN A CHEMOTHERAPY PLAN FOR BREAST CANCER PATIENTS
JP6164689B2 (ja) * 2013-08-30 2017-07-19 国立大学法人大阪大学 乳癌術前化学療法に対する感受性の診断補助方法および判定装置
PL228355B1 (pl) * 2013-10-15 2018-03-30 Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia Sposób wykrywania obnizonej podatnosci na przeciwnowotworowa chemioterapie adjuwantowa cytostatykiem z grupy oksazofosforyn i antybiotykiem z grupy antracyklin u pacjentów z inwazyjnym przewodowym rakiem gruczołu piersiowego (IDC)
US20160348183A1 (en) * 2014-02-12 2016-12-01 Myriad Genetics, Inc. Method for predicting the response and survival from chemotherapy in patients with breast cancer
EP3310260A4 (en) * 2015-06-22 2019-03-06 Sunnybrook Research Institute SYSTEMS AND METHOD FOR PREDICTING THE TUMOR RESPONSE TO CHEMOTHERAPY USING QUANTITATIVE ULTRASOUND PARAMETERS OF PRE-TREATMENT
US11497476B2 (en) * 2015-06-22 2022-11-15 Sunnybrook Research Institute Systems and methods for prediction of tumor treatment response to using texture derivatives computed from quantitative ultrasound parameters
EP3679160A4 (en) 2017-09-08 2021-05-19 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY
EP3856933A1 (en) * 2018-09-27 2021-08-04 BioNTech Diagnostics GmbH Predictive and prognostic methods in breast cancer
EP3887548A1 (en) 2018-11-30 2021-10-06 GBG Forschungs GmbH Method for predicting the response to cancer immunotherapy in cancer patients
CN113061655B (zh) * 2021-03-25 2022-04-19 中国科学院合肥物质科学研究院 一组用于预测乳腺癌新辅助化疗敏感性的基因标签及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608643A1 (en) 2005-05-13 2006-11-16 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US20090239223A1 (en) 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
WO2010076322A1 (en) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
HUE030164T2 (en) 2010-03-31 2017-05-29 Sividon Diagnostics Gmbh A method of predicting breast cancer recurrence during endocrine treatment

Also Published As

Publication number Publication date
US20170081728A1 (en) 2017-03-23
ES2714582T3 (es) 2019-05-29
HUE032391T2 (en) 2017-09-28
US20190144949A1 (en) 2019-05-16
ES2608322T3 (es) 2017-04-07
WO2013014296A1 (en) 2013-01-31
US20140228241A1 (en) 2014-08-14
PT2737081T (pt) 2016-12-23
EP3150720A1 (en) 2017-04-05
EP2737081B1 (en) 2016-09-28
EP2737081A1 (en) 2014-06-04
US20220307090A1 (en) 2022-09-29
EP3150720B1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
IL276488A (en) A method for predicting the prognosis of breast cancer
PT2737081T (pt) Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente
HK1203091A1 (en) Methods for diagnosis of lung cancer
HK1254859A1 (zh) 治療乳腺癌的方法
HK1212022A1 (en) Methods for predicting risk of developing hypertension
IL228738A0 (en) Antibodies for cancer treatment
GB201102014D0 (en) Method for predicting risk of developing cancer
EP2613151A4 (en) METHOD OF DETERMINING THE APPEARANCE OF CANCER OR THE RISK OF APPEARANCE OF CANCER
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
GB2513275B (en) Biomarkers for Breast Cancer Prediction and Diagnosis
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
EP2668295A4 (en) METHODS OF DETECTING LUNG CANCER
IL228579A0 (en) Methods for predicting and improving the survival of gastric cancer patients
LT3141617T (lt) Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją
EP2742358A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2699699A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2894477A4 (en) METHOD FOR DETECTION OF BREAST CANCER
HK1204481A1 (en) Method for in vitro diagnosis or prognosis of colon cancer
EP2771695A4 (en) METHOD OF DETECTION OF BREAST CANCERS
EP2661505A4 (en) SYSTEM AND METHOD FOR DETERMINING THE PROGNOSIS OF CANCER AND PREDICTING A RESPONSE TO THERAPY
EP2726880A4 (en) TREATMENT OF PROSTATE CANCER AND METHOD FOR DETERMINING THE PROGNOSIS OF PROSTATE RAY PATIENTS
EP2732287A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2769225A4 (en) BIOLOGICAL MARKERS PREDICTIVE FOR BREAST CANCER
EP2721410A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER
IL231330A0 (en) Cancer diagnosis methods